Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases

1 Department of Gastroenterology and Hepatology, Saint-Andr é Hospital, University Hospital of Bordeaux and Victor Segalen University, Bordeaux, France, 2 Department of Pathology, Pellegrin Hospital, University Hospital of Bordeaux and Victor Segalen University, Bordeaux, France, 3 Department of Radiology, Saint Andr é Hospital, University Hospital of Bordeaux, and Victor Segalen University, Bordeaux, France and 4 Department of Digestive Surgery, Saint Andr é Hospital, University Hospital of Bordeaux and Victor Segalen University, Bordeaux, France

[1]  S. Kakolyris,et al.  Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report , 2011, Medical oncology.

[2]  M. Kudo,et al.  Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report , 2011, Oncology.

[3]  A. Santoro,et al.  Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. , 2011, World journal of gastroenterology.

[4]  M. Ronot,et al.  Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[5]  X. Pivot,et al.  Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Bartolozzi,et al.  Complete response for advanced liver cancer during sorafenib therapy: Case Report , 2011, BMC gastroenterology.

[7]  M. Kudo,et al.  Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan , 2010, Oncology.

[8]  S. Verma,et al.  Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report , 2010, Targeted Oncology.

[9]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[10]  R. Finn,et al.  Apparent Remission of a Solitary Metastatic Pulmonary Lesion in a Liver Transplant Recipient Treated with Sorafenib , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[12]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[13]  T. Bekaii-Saab,et al.  Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report , 2008, Journal of hematology & oncology.

[14]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[15]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.